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Summary Immunophenotyping of haematological malignancies has developed as a clinically valuable
but technically complicated diagnostic procedure. It involves a variety of methodological
features, in-process strategic judgements and an extensive knowledge of clinical, mor-
phological and other laboratory features of the disease processes under study. We discuss
the various internal quality control steps necessary to guarantee reliable results with respect
to instrument set-up and calibration; sample preparation; selection and validation of mono-
clonal antibody panels; and flow cytometric data acquisition, analysis and interpretation of
results. The quality of the entire procedure is documented by the analysis of representative
specimens in the setting of an external quality assurance programme.
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Introduction
Immunophenotyping is a widely accepted diagnostic tool
for many haematological malignancies in the context of
clinical, morphological and cytogenetic data. Flow cyto-
metry is regarded as the method of choice for immuno-
phenotyping because it is fast, objective, quantitative and
amenable to standardization (Jennings & Foon 1997). Flow
cytometric immunophenotyping is an essential part of the
diagnostic procedure in acute lymphoblastic and myeloid
leukaemias (ALL and AML) and chronic lympho-
proliferative disorders, and its results constitute useful
information for therapeutic decision-making in these
diseases. Also, flow cytometric monitoring during residual
disease may have diagnostic and therapeutic utility in pa-
tients with acute leukaemia (Brisco et al. 1996; Davis et al.
1997; San Miguel et al. 1997).
Importantly, flow cytometric immunophenotyping of
haematological malignancies is not a simple and stan-
dardized assay which provides precise numerical results
carrying direct diagnostic information. The various
methodological steps, the interpretation of the data and
the clinical significance of the results require substantial
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participation and critical judgement by the laboratory pro-
fessionals involved. Adequate quality control (QC) pro-
cedures are therefore essential. We discuss the consecutive
steps during the entire flow cytometric immuno-
phenotyping assay with special emphasis on the various
internal QC procedures to be performed. We refer the reader
for an extensive discussion of these procedures to the con-
sensus recommendations that have been formulated by
experts in Europe (Rothe et al. 1996) and in the US and
Canada (Borowitz et al. 1997; Braylan et al. 1997a,b; Davis
et al. 1997; Stelzer et al. 1997; Stewart et al. 1997).
In addition to performing internal QC, participation in
an external quality assessment (EQA) programme is useful
for each laboratory involved in immunophenotyping
haematological malignancies to document the overall qual-
ity of its output. The UK National External Quality Assess-
ment Schemes (NEQAS) provide send-outs of stabilized
whole blood specimens from patients with haematological
malignancies to laboratories in the UK and abroad, followed
up by written evaluations (Barnett, Granger & Reilly 1994).
The Dutch Foundation for the Immunophenotyping of
Hematological Malignancies (SIHON) organizes biannual
send-outs of cryopreserved mononuclear cell suspensions
to laboratories in the Netherlands and Belgium, followed
up by plenary educational meetings (Kluin-Nelemans et al.
1996). Although participation in an EQA programme is
currently on a voluntary basis, it is expected that it will
become compulsory in the near future as part of laboratory 155
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accreditation for the immunophenotyping of leukaemias
and lymphoproliferations.
Instrument set-up and calibration
To ensure that the flow cytometer performs adequately
for any given application, the instrument must be set up
appropriately and its performance in measuring flu-
orescence (FL) intensity must be verified. The design and
manufacture of a range of microbead (reviewed by Sch-
wartz et al. 1998) and cellular control materials has been
pivotal in reaching this goal. To assure optimal instrument
performance, two groups of procedures must be performed.
The first group of procedures is carried out at relatively
infrequent intervals (e.g. once every 6 months) by qualified
service personnel and includes an examination of the
efficiency and performance of the laser tube, optical filters,
log and linear amplifiers, and photomultiplier tubes (PMT)
of all types of flow cytometers. These procedures also
include a calibration of the optical alignment in flow cyto-
meters of the ‘stream-in-cuvette’ type, which constitutes
the majority of instruments in use for clinical diagnostic
procedures. However, the optical alignment of flow cyto-
meters with sorting facilities, which are equipped with a
nozzle (‘stream-in-air’ type), must be calibrated at each
‘cold start’ by the instrument operators owing to their
relative instability.
The second group of procedures consists of frequent (i.e.
at each ‘cold start’ of the instrument for a given application)
monitoring of instrument set-up and performance by the
operators to identify both immediate and potential prob-
lems (see Schwartz et al. 1996 and Stelzer et al. 1997 for
detailed protocols). Optimal instrument set-up implies that
all cellular populations are visible on each FL or light scatter
scale. This optimization is performed with a representative
stained cell specimen. For forward (FSC) and sideward (SSC)
light scatter analysis, linear amplification is generally used,
although logarithmic amplification is more useful for the
simultaneous visualization of normal and aberrant cell
populations with high SSC signals, such as hairy leukaemia
cells, plasma cells or cells derived from solid tumours. For
FL analysis, logarithmic amplification is generally used
because of the wide dynamic range of FL intensities in most
biological samples.
Having done so, the correction must be set for the vari-
able levels of overlap between the emission spectra of rou-
tinely used dyes such as the green-fluorescent dye
fluorescein isothiocyanate (FITC), the orange-fluorescent
dye phycoerythrin (PE), and the red-fluorescent dyes peri-
dinin chlorophyll (PerCP), PE-Cy5 or allophycocyanin
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(APC). The establishment of appropriate colour com-
pensation for any number of dyes requires an equal number
of cell suspensions single-labelled with monoclonal anti-
bodies conjugated to those dyes, plus one suspension
stained with all dyes. Each cell population should span the
FL intensities ranging from weakly positive to a rep-
resentative high for that assay. Electronic compensation
for spectral overlap can be set manually or automatically
through the use of certain software packages.
After establishing appropriate application-specific
instrument settings, the target channels for the relevant FL
parameters are recorded using fluorescent reference beads.
The use of these target channels allows, at subsequent
occasions, a rapid and reliable verification of the instrument
settings. For light scatter parameters, it suffices to run a
representative specimen and to verify that all major cell
populations are in their typical positions in the FSC vs. SSC
dotplot.
The performance of the instrument in quantitative FL
measurements is monitored by computing calibration plots
for each FL parameter from data generated by the measure-
ment of calibration beads labelled with the relevant dyes in
different pre-defined intensities. Trends and variations are
documented using Levey–Jennings style charts (Levey &
Jennings 1950) that allow the visual inspection of longi-
tudinal data for monitoring instrument performance for
precision and trends. If any value falls outside the tolerance
limits, the monitoring should be repeated and the instru-
ment settings adjusted if the problems persist.
Sample preparation
The range of specimens submitted for the immuno-
phenotyping of haematological malignancies includes not
only venous blood, but frequently bone marrow aspirates
and also visceral fluid samples. Collection of the latter types
of specimens involves more invasive procedures with more
patient discomfort than venepuncture. Therefore, a more
liberal policy for specimen rejection is warranted than
would be usual, e.g. for enumeration of lymphocyte subsets.
However, acceptance of compromised specimens for pro-
cessing implies that strict and detailed flagging criteria must
be used, such as the clotting or haemolysis of bone marrow
aspirates or the presence of erythrocytes in liquor samples.
Flow cytometry requires that a single cell suspension
is prepared for analysis. Clots and bone spicules may be
disrupted using a filter mesh. Most importantly, the risk
that the cells of interest, i.e. the abnormal cells, are lost
during sample preparation should be minimized. The avail-
ability of multiple (i.e.  5) parameter flow cytometry
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allows the analysis of highly complex cellular mixtures.
Owing to this, the removal of neutrophils and dead cells by
density gradient centrifugation is no longer necessary. Still,
current flow cytometric technology requires the physical
removal of erythrocytes from blood and bone marrow aspi-
rates, in which they typically outnumber leucocytes by
approximately a thousand-fold. Hypotonic erythrocyte lysis
carries a smaller risk of loosing abnormal cells than density
gradient separation: the latter method is optimized for lym-
phocyte isolation and abnormal cells that do not have a
similar buoyant density as lymphocytes will not be found
where expected in the gradient. Therefore, erythrocyte lysis
is recommended over gradient separation for immuno-
phenotyping haematological malignancies (Stelzer et al.
1997). Importantly, the cell suspensions prepared for flow
cytometry should be representative of the fraction of the
sample that may contain the abnormal cells. This control
can be obtained by comparing the flow cytometric results
with cytochemically stained smear preparations of peri-
pheral blood and bone marrow aspirates, and cytospin
preparations from visceral fluid samples.
The policy of making every attempt to obtain useful
information from each specimen, regardless of its condition,
requires that viable and dead nucleated cells be
distinguished. Dead cells can severely compromise an
immunophenotypic analysis because the damaged surface
membrane of such cells may allow the nonspecific uptake
of monoclonal antibodies, leading to nonspecific FL signals.
The addition of a dye identifying dead cells to all staining
cocktails of such samples allows the exclusion of dead cells
during data acquisition or during analysis. Useful dyes
are 7-amino-actinomycin D (7-AAD) for unfixed samples
(Schmid et al. 1992) or ethidium monoazide (EMA) for sam-
ples that are to be fixed (Riedy et al. 1991).
The integrity of the cellular surface membrane is thus a
prerequisite for the reliable detection of cell surface anti-
gens. The intracellular or surface membrane localization of
some markers is crucial for the interpretation of staining
results (e.g. cytoplasmatic CD3 : immature and surface
membrane CD3 : mature T lineage cells). Fixation and
permeabilization for intracellular antigen detection should
therefore be performed after the completion of surface stain-
ing. Any method used for fixation and permeabilization
must preserve the expression and antigenicity of the mar-
kers to be evaluated.
Finally, the number of lymphocyte subsets per unit vol-
ume of peripheral blood contributes useful information for
monitoring chronic lymphoproliferative diseases. Such
absolute cell counts can reliably be obtained by flow cyto-
metry of a single immunophenotyping staining through
the addition of a known number of brightly fluorescent
counting beads (Gratama et al. 1998a).
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Selection and validation of monoclonal antibody
panels
Any choice of monoclonal antibody combinations for the
initial investigation of haematological malignancies must
allow the distinction of neoplastic cells from their normal
counterparts as well as the enumeration and further
characterization of the neoplastic cells. From the 166 clus-
ters of differentiation (CD) defined in 1996 (Kishimoto et al.
1997) and the numerous unclustered antigens, some 40–
50 bear direct relevance for this purpose (Rothe & Schmitz
1996; Stewart et al. 1997). Neoplastic haematopoietic cells
not only reflect, to a certain extent, normal cellular matu-
ration, but they also show frequently aberrant phenotypes
that distinguish them from their normal counterparts. Such
‘malignant’ phenotypes have been reported in 90% of ALL,
75% of AML and 90% of monoclonal plasma cell pro-
liferations (Jennings & Foon 1997). The use of at least 5
parameters (forward (FSC) and sideward (SSC) light scatter
plus 3 FL parameters) is essential to resolve complex,
aberrant immunophenotypes in the many clinical speci-
mens that also contain significant proportions (i.e.  80%)
of normal cells.
Given the large number of monoclonal antibody com-
binations possible in triple and even quadruple marker
stainings only general recommendations can be given for
the selection of monoclonal antibody panels (Stewart et al.
1997). Depending on the organization of each laboratory
and the (available information on the) submitted speci-
mens, one-step diagnostic strategies may consist either of
a single, comprehensive monoclonal antibody panel, or of
a choice between a limited number of targeted panels. The
latter should contain a few ‘safeguard’ stainings in case the
clinical information, on which the panel choice has been
based, is wrong (van ‘t Veer et al. 1992). The alternative
two-step approach consists of a small screening panel fol-
lowed by a larger, targeted panel. Advantages of the single-
step comprehensive panel are extensive information and
minimal requirement of in-process strategic judgements;
disadvantages are high reagent costs and inapplicability to
samples with low cell counts. The targeted approaches
imply more in-process strategic judgements and may be
more time-consuming, but save on reagent costs. In short,
there is no single ‘golden rule’ for defining monoclonal
antibody panels.
For the follow-up of a given haematological malignancy,
a targeted approach tailored to the ‘malignant’ phenotype
is appropriate. In this context, the judicious selection of a
few three or four-colour monoclonal antibody cocktails is
critical to obtain an appropriate sensitivity and specificity
for the detection of minimal residual disease. Still, sufficient
safeguards must be built in to enable the detection of emerg-
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ing malignant subpopulations with an immunophenotype
that differs from the original (San Miguel et al. 1997).
Whatever the strategy of the laboratory, the chosen
panel(s) of monoclonal antibody combinations must be
validated. Firstly, the monoclonal antibody conjugates
should be chosen such that spectral overlap can be
adequately controlled. PE is preferred as dye for monoclonal
antibody-detecting antigens expressed at a low intensity
because of its high quantum yield and lack of interference
by cellular autofluorescence in comparison to FITC.
Secondly, no steric hindrance should occur between the
monoclonal antibodies in each cocktail. Therefore, the
monoclonal antibodies labelled in combination should yield
FL signals of the same intensity as that obtained in single-
colour stainings. Thirdly, the amount of monoclonal anti-
body used for staining must be verified for the staining
procedure and type of samples used. The manufacturers’
recommendations are often only based on staining with
normal cells. Nonspecific monoclonal antibody-binding
should be minimized whilst at the same time retaining
maximum discrimination between positive and negative
cell populations. The chosen amount of monoclonal anti-
body for staining must be verified whenever a new batch
of monoclonal antibody is put into use. This control is
conveniently performed by comparing the performance of
the old and new batches on an informative cell suspension.
We agree with the US–Canadian consensus recom-
mendations (Stelzer et al. 1997) that a positive procedure
control (i.e. cells of a healthy donor) and isotype control
stainings are redundant. Even specimens dominated by an
abnormal population will contain at least a few residual
normal cells which serve as benchmark for an appropriate
staining technique. Any fluorochrome and isotype control
monoclonal antibody is by definition not representative for
the great variety of used monoclonal antibodies with their
different protein concentrations and fluorochrome to pro-
tein ratios. Instead, any monoclonal antibody panel will
yield at least a few negative populations for each fluo-
rochrome that can serve as control for nonspecific mon-
oclonal antibodies binding in comparison to unstained cells
as an autofluorescence control. (Cellular autofluorescence
is increased in some AML cases and during cytoreductive
treatment with anthracyclins.)
Flow cytometric data acquisition, analysis, and
interpretation of results
Different strategies to acquire and analyse flow cytometric
data are used for the initial investigation of haematological
malignancies and for follow-up studies. As stated above,
the objective of the initial investigation is twofold, to resolve
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the abnormal population from the normal population, and
to characterize the abnormal cells in more detail. For that
purpose, a sufficient number of viable cells (typically
10 000–20 000 per staining) should be acquired. The
abnormal cells can be identified on the basis of qualitative
(i.e. an aberrant phenotype) and/or quantitative data (i.e.
the abnormal population cannot be resolved phenotypically
from its normal counterparts other than by its exceedingly
high frequency in the sample). An appreciation of the nor-
mal ranges is essential for the correct interpretation of such
data. Non-malignant blood and bone marrow samples from
some tens of individuals of the relevant age range, analysed
with the monoclonal antibody cocktails for an initial diag-
nosis in the relevant technique, may constitute a reference
source in this respect.
Further characterization of the abnormal population is
typically performed by ‘gating’, i.e. the selection of a specific
group of cells on the basis of a (combination of) parameters.
These parameters should be detectable in subsequent stain-
ings if all necessary information cannot be retrieved from
a single staining. A discussion of detailed gating techniques
is outside the scope of this overview. There are two major
strategies. In the first, termed sequential gating, events are
selected on the initial dotplot or histogram and subsequent
gates are placed on the selected events in a cumulative
manner (Gratama et al. 1998a). An alternative strategy is
to keep all dots on screen and to select the relevant cells by
combining different regions in different dotplots based on
simultaneous gating. According to this technique, cells
fulfilling the criteria of two or more different regions are
pseudo-colour coded and separately analysed without
removing non-relevant cells from the display. This
approach was first used in the Paint-A-GATETM software
(Becton Dickinson Immunocytometry Systems, San Jose,
CA, USA) and is currently available within a variety of
software packages from different manufacturers.
With the abolition of the isotype control stainings, the
traditional practice of setting a threshold on the negative
population to subsequently calculate the ‘percentage posi-
tives’ by applying this threshold to a single-colour his-
togram of a stained population, is now considered
inappropriate for immunophenotyping haematological
malignancies (Borowitz et al. 1997). Information conveyed
in this way is only accurate if the gated population is
pure and the FL distribution is bimodal with well-separated
peaks (e.g. CD4+ cells within a population of CD3+ T lym-
phocytes). Thus, a qualitative description of the abnormal
cell population with respect to additional markers is
informative and sufficient.
Importantly, the resolution of flow cytometric immuno-
phenotyping of haematological malignancies can be fur-
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ther improved by taking FL intensity (approximate density
of antigen expression) into account whilst interpreting the
data. Useful examples are the low to absent expression of
CD45 by AML and ALL blasts (Borowitz et al. 1993) and
the weak expression of CD20 by B-chronic lymphatic leu-
kaemia cells (Marti et al. 1992). Research methodologies
are now available to express this information in a quan-
titative manner (reviewed by Gratama et al. 1998b).
However, it remains to be established whether or not such
quantification increases the diagnostic power of the assay
as compared to the simple, qualitative description of
aberrant levels of FL intensity relative to normal reference
populations in the sample.
Follow-up studies of haematological malignancies serve
to monitor the extent of disease, whilst being vigilant for
emerging malignant subpopulations with an immuno-
phenotype differing from the original. Low-level minimal
residual disease can only be detected if the detected pheno-
type of the malignant cells is absent or extremely infrequent
in normal samples. Reliable detection of minimal residual
disease requires that the aberrant cells can be detected as
a cluster (i.e. at least 50 events) in a bivariate dotplot of
gated events. This approach often requires the collection of
very large list mode data files (e.g. up to 106 events). As
the residual malignant cells are ‘rare events’ in such
samples, their number will follow a Poisson distribution.
According to such a distribution, their CV (in percentage)
is 100  sqrt(n) 6 n, in which n = number of events fulfil-
ling the criteria of the malignant cells. Hence, their CV will
vary proportionally to the square root of the number of
residual malignant cells acquired. For example, acquiring
50 of such cells yields a CV of 100  sqrt(50) 6 50 = 15%.
The final control of each immunophenotypic inves-
tigation occurs with formulating the summary conclusion.
The immunological information should then be combined
with appropriate clinical, morphological and other lab-
oratory information. Therefore, the professionals respon-
sible for the final interpretation and signature of the
immunophenotyping report must possess a combined
knowledge of the laboratory and clinical manifestations of
haematological malignancies, as well as practical experi-
ence in analytical flow cytometry. The final interpretation
of a disease condition that influences patient management
can only be given by the physician in charge (Braylan et al.
1997b).
The future: consequences for external quality
assurance surveys
During the past 10 years, flow cytometric immuno-
phenotyping of haematological malignancies has evolved
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from single-colour analysis of surface membrane antigens
expressed by gradient-isolated mononuclear cells to sim-
ultaneous four-colour analyses of surface membrane and
intracellular antigens in cell suspensions that resemble the
native specimen as closely as possible. This technical pro-
gress has greatly enhanced the diagnostic power of the
technique in resolving minor populations of aberrant cells
in otherwise normal samples. The emerging clinical rel-
evance of the detection of minimal residual disease (Brisco
et al. 1996; Davis et al. 1997; San Miguel et al. 1997)
requires that EQA programmes not only survey the capa-
bility of laboratories to immunophenotype and interpret
specimens dominated by malignant cells, but also docu-
ment their ability to resolve low-frequency aberrant popu-
lations. In this context it is important that the distributed
test specimens resemble the original ones as much as poss-
ible without artefacts incurred by storage and transport.
The performance of EQA programmes such as those organ-
ized by UK NEQAS and SIHON are pivotal in approaching
these goals.
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